Last reviewed · How we verify
NCT06656234
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
trial testing Glofitamab in Diffuse Large B Cell Lymphoma (DLBCL) in 200 participants. Not yet recruiting.
15 September 2027
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 30 October 2024 |
| Primary completion | 15 September 2027 |
| Estimated completion | 15 September 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Glofitamab (glofitamab) — full drug profile →
- Obinutuzumab — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B Cell Lymphoma (DLBCL) →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with Diffuse Large B Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06656234
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Glofitamab
Trials testing the same drug.
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R · Phase 2 · recruiting
- NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
- NCT07453095 — Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy · Phase 2 · not yet recruiting
- NCT07387848 — Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lym · Phase 2 · not yet recruiting
Other recruiting trials for Diffuse Large B Cell Lymphoma (DLBCL)
Currently open trials in the same condition.
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
- NCT07371923 — Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
- NCT07062627 — Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma · Phase 2 · recruiting
- NCT07260812 — KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · recruiting
- NCT07124936 — A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06656234 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06656234.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing